Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Up 7.22%
As of Tuesday, August 04, Palvella Therapeutics, Inc.’s PVLA share price has surged by 7.22%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
Commentary & Analysis
Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Down 5.29%
As of Friday, July 31, Palvella Therapeutics, Inc.’s PVLA share price has dipped by 5.29%, which has investors questioning if this is right time to buy.Michael Rose
Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Up 5.23%
As of Tuesday, July 21, Palvella Therapeutics, Inc.’s PVLA share price has surged by 5.23%, which has investors questioning if this is right time to sell.Michael Rose
Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Up 13.35%
As of Tuesday, July 21, Palvella Therapeutics, Inc.’s PVLA share price has surged by 13.35%, which has investors questioning if this is right time to sell.Tudor Pop
Why Palvella Therapeutics, Inc.’s (PVLA) Stock Is Down 7.06%
As of Monday, July 20, Palvella Therapeutics, Inc.’s PVLA share price has dipped by 7.06%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | PVLA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $2,054.4 | $286.3 | 54% |
|
| Shares Out (Mil) | 14.4 | 54.2 | 25% |
|
| Institutional Ownership | 91.2% | 92.8% | 60% |
|
| Float (Mil) | 10.6 | 39.7 | 20% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 179 | 534 | 42% |
|
| Price Change (52-week) |
194.0% | 58.7% | 97% |
|
| Growth | PVLA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 13 | 10 | |
| Current EPS | ($1.735) | ($6.371) | ($7.498) | |
| Month Ago EPS | ($1.465) | ($5.565) | ($6.384) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 1 | 3 | |
| Three Months Ago EPS | ($1.467) | ($5.567) | ($6.682) | |
| Year/Year Chg | 13.9% | 71.8% | 52.1% | |
| Financials | PVLA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($62) | ($43) | 14% |
|
| EPS (TTM) | ($4.898) | ($1.400) | 8% |
|
| Operating Cash Flow (TTM) (Mil) | ($37) | ($31) | 11% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $22 | $4 | 33% |
|
| Enterprise Value (Q1) (Mil) | $1,962 | $160 | 49% |
|
| Valuation | PVLA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 9.47 | 2.77 | 89% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | PVLA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (37.7%) | (47.3%) | 14% |
|
| ROE | (46.6%) | (55.0%) | 16% |
|
| Liabilities to Assets | 14.5% | 29.6% | 9% |
|
| F-Score | 4 | 2 | 34% |
|
Palvella Therapeutics, Inc. did not pass any screens on 8/20/2026.
